Advisory Services Network’s Ultragenyx Pharmaceutical RARE Stock Holding History

Advisory Services Network’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-20	Closed	-$602	–	3700
2025 Q3	$602	Buy	+20	New	+$600	﹤0.01%	4019
2024 Q1	–	Sell	-1	Closed	-$48	–	3155
2023 Q4	$48	Buy	+1	New	+$39	﹤0.01%	3812
2023 Q2	–	Sell	-1	Closed	-$40	–	3140
2023 Q1	$40	Hold	1	–	–	﹤0.01%	3932
2022 Q4	$46	Buy	+1	New	+$39	﹤0.01%	3945
2020 Q4	–	Sell	-16	Closed	-$1.9K	–	3630
2020 Q3	$1K	Buy	+16	New	+$1.33K	﹤0.01%	3382
2020 Q1	–	Sell	-25	Closed	-$1K	–	3243
2019 Q4	$1K	Buy	+25	New	+$1.03K	﹤0.01%	2994

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Advisory Services Network's RARE Position: Q4 2025 in Review

Advisory Services Network sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 20 shares — an estimated $602 sold.

Advisory Services Network first reported a position in RARE in Q4 2019 and held it in 6 quarters. The position peaked at $1K in Q3 2020. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Advisory Services Network reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Advisory Services Network sold 20 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $602.
Advisory Services Network first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 6 quarters.
Advisory Services Network's Ultragenyx Pharmaceutical position peaked at $1K in Q3 2020.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Advisory Services Network's 13F filing for Q4 2025, filed 17 Feb 2026.